Dash Ashutosh, Pillai Maroor Raghavan Ambikalmajan, Knapp Furn F
Isotope Production and Applications Division, Bhabha Atomic Research Centre (BARC), Trombay, Mumbai 400 085 India.
Molecular Group of Companies, Kochi, 780001 Kerala India.
Nucl Med Mol Imaging. 2015 Jun;49(2):85-107. doi: 10.1007/s13139-014-0315-z. Epub 2015 Feb 17.
This review provides a comprehensive summary of the production of (177)Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of (177)Lu having the required quality for preparation of a variety of (177)Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of (177)Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success.
While both "direct" and "indirect" reactor production routes offer the possibility for sustainable (177)Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies.
This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future.
A broad understanding and discussion of the issues associated with (177)Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of (177)Lu-labeled radiopharmaceuticals, but also help future developments.
本综述全面总结了¹⁷⁷Lu的生产情况,以满足未来预期的研究和临床需求。多种选择的存在是¹⁷⁷Lu常规生产可持续增长的基石,要生产出具有制备各种¹⁷⁷Lu标记放射性药物所需质量的足够活度水平的¹⁷⁷Lu。¹⁷⁷Lu用于靶向放射性核素治疗(TRT)的巨大前景表明,应从整体上考虑所有决定其成功的关键因素。
虽然“直接”和“间接”反应堆生产路线都为¹⁷⁷Lu的可持续供应提供了可能性,但要充分发挥这些生产策略的潜力,还必须考虑若干问题和挑战。
本文对最新进展、现状、关键挑战以及近期的可能性进行了简要综述。
对与¹⁷⁷Lu生产和加工方法相关的问题进行广泛的理解和讨论,不仅能确保¹⁷⁷Lu标记放射性药物的供应和使用实现持续增长及未来扩展,还将有助于未来的发展。